{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000054","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-09-09T11:43:19+00:00","discovered_at":"2026-09-09T11:45:01.009438+00:00","generated_at":"2026-09-09T11:45:05.267514+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina's SER-252 Phase 1b Cohort 1 clears safety review; advances to Cohort 2","bullets":["Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety/tolerability data.","Cohort 1 (lowest dose, n=8) showed sustained apomorphine exposure and motor function improvements in individual patients.","Topline data from single-ascending-dose portion expected in first half of 2027.","Study is randomized, double-blind, placebo-controlled; 5 cohorts of 8 in SAD portion, then MAD portion."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000054","json":"https://secwatch.observer/filing/0001708599-26-000054.json","markdown":"https://secwatch.observer/filing/0001708599-26-000054.md","text":"https://secwatch.observer/filing/0001708599-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/0001708599-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/ser-20260909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T11:45:05.267514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}